Nicholas Dracopoli,
Vice President/Head,
Johnson & Johnson
Dr. Nicholas Dracopoli is Vice President, Head Oncology Biomarkers at Janssen R&D, Johnson & Johnson. In this role he is responsible for biomarker discovery, development and applications for oncology products. Previously, he was Vice President of Clinical Discovery Technologies at Bristol-Myers Squibb, and prior to that spent five years in the biotechnology industry at Sequana Therapeutics. Dr Dracopoli obtained his B.Sc. and Ph.D. degrees from the University of London, and completed post-doctoral fellowships at the Memorial Sloan-Kettering Cancer Center and the Massachusetts Institute of Technology (MIT). Subsequently, he served as an Assistant Director at the Whitehead/MIT Genome Center, and as a Section Chief at the National Center for Human Genome Research at the NIH before moving to the biotechnology industry. Dr Dracopoli has authored >70 scientific publications, and has extensive experience in the fields of genomics, molecular biology and cancer research.
|
.png)
|
Big Data and Small Trials: Translating Biological Data into Clinical BiomarkersTuesday, 28 October 2014 at 14:00 All of the companion diagnostic tests approved by the FDA for use in oncology are for “driver mutations” in genes involved in signal transduction pathways. These tests are for single analytes predicting the functional status of the drug target or pathway. There are no approved companion diagnostics for drugs that work through alternative mechanisms such as chemotherapy or immunomodulation. This presentation will discuss why so few biomarkers have been developed, and why we have mostly failed to develop molecular profiles that predict drug response.
|
Add to Calendar ▼SELECTBIOenquiries@selectbiosciences.com
